Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Bionano Genomics Inc is a diagnostics & research business based in the US. Bionano Genomics shares (BNGO) are listed on the NASDAQ and all prices are listed in US Dollars. Bionano Genomics employs 147 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $2.05 |
|---|---|
| 52-week range | $1.81 - $15.69 |
| 50-day moving average | $3.48 |
| 200-day moving average | $5.36 |
| Wall St. target price | $12.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.25 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.05 from 2022-01-25
| 1 week (2022-01-19) | -11.64% |
|---|---|
| 1 month (2021-12-23) | -36.73% |
| 3 months (2021-10-26) | -60.27% |
| 6 months (2021-07-26) | -65.08% |
| 1 year (2021-01-26) | -83.21% |
|---|---|
| 2 years (2020-01-24) | 76.72% |
| 3 years (2019-01-25) | 4.41 |
| 5 years (2017-01-22) | N/A |
| Revenue TTM | $15.7 million |
|---|---|
| Gross profit TTM | $2.8 million |
| Return on assets TTM | -18.06% |
| Return on equity TTM | -34.37% |
| Profit margin | 0% |
| Book value | $1.21 |
| Market capitalisation | $592.8 million |
TTM: trailing 12 months
We're not expecting Bionano Genomics to pay a dividend over the next 12 months.
Over the last 12 months, Bionano Genomics's shares have ranged in value from as little as $1.8112 up to $15.69. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Bionano Genomics's is 1.7525. This would suggest that Bionano Genomics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Bionano Genomics, Inc. , a genome analysis company, provides tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing. Its Saphyr system is a research use only platform for ultra-sensitive and ultra-specific structural variation detection that enables scientists and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. The company also provides diagnostic testing for those with autism spectrum disorder and other neurodevelopmental disabilities. In addition, it offers an agnostic cross-platform data interpretation and clinical reporting software that integrates next-generation sequencing and microarray data, and provides visualization of copy number variants, single-nucleotide variants, and absence of heterozygosity across the genome for a fully integrated analysis in one view. The company was founded in 2006 and is headquartered in San Diego, California. .
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Read our expert analysis on Vigorus and how the token will perform in the future.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Everything we know about the Austin Gold IPO, plus information on how to buy in.